dc.contributor.author | Mączyńska, J | |
dc.contributor.author | Da Pieve, C | |
dc.contributor.author | Burley, TA | |
dc.contributor.author | Raes, F | |
dc.contributor.author | Shah, A | |
dc.contributor.author | Saczko, J | |
dc.contributor.author | Harrington, KJ | |
dc.contributor.author | Kramer-Marek, G | |
dc.date.accessioned | 2021-02-04T15:45:57Z | |
dc.date.available | 2021-02-04T15:45:57Z | |
dc.date.issued | 2020-10-20 | |
dc.identifier.citation | Cell death & disease, 2020, 11 (10), pp. 886 - ? | |
dc.identifier.issn | 2041-4889 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4336 | |
dc.identifier.eissn | 2041-4889 | |
dc.identifier.doi | 10.1038/s41419-020-03077-6 | |
dc.description.abstract | There is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological responses by releasing tumour-associated antigens from ablated tumour cell residues, thereby enhancing antigenicity and adjuvanticity. Here, we investigate the feasibility of a novel HER2-targeted affibody-based conjugate (ZHER2:2395-IR700) selectively to induce cancer cell death in vitro and in vivo. The studies in vitro confirmed the specificity of ZHER2:2395-IR700 binding to HER2-positive cells and its ability to produce reactive oxygen species upon light irradiation. A conjugate concentration- and light irradiation-dependent decrease in cell viability was also demonstrated. Furthermore, light-activated ZHER2:2395-IR700 triggered all hallmarks of immunogenic cell death, as defined by the translocation of calreticulin to the cell surface, and the secretion of ATP, HSP70/90 and HMGB1 from dying cancer cells into the medium. Irradiating a co-culture of immature dendritic cells (DCs) and cancer cells exposed to light-activated ZHER2:2395-IR700 enhanced DC maturation, as indicated by augmented expression of CD86 and HLA-DR. In SKOV-3 xenografts, the ZHER2:2395-IR700-based phototherapy delayed tumour growth and increased median overall survival. Collectively, our results strongly suggest that ZHER2:2395-IR700 is a promising new therapeutic conjugate that has great potential to be applicable for photoimmunotherapy-based regimens. | |
dc.format | Electronic | |
dc.format.extent | 886 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGERNATURE | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Immunomodulatory activity of IR700-labelled affibody targeting HER2. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-10-01 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/s41419-020-03077-6 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-10-20 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cell death & disease | |
pubs.issue | 10 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Preclinical Molecular Imaging | |
icr.researchteam | Targeted Therapy | |
icr.researchteam | Preclinical Molecular Imaging | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Da Pieve, Chiara | |
dc.contributor.icrauthor | Harrington, Kevin | |
dc.contributor.icrauthor | Kramer-Marek, Gabriela | |